GlassScriptPhysician profile
Von Hoang
NPI 1275921223
$9,189.96
in general payments reported to CMS, 2019-2025
63 companies · $19.25 in 2025
The $19.25 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,529 · 2022: $3,669 · 2023: $456 · 2024: $518 · 2025: $19.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.53 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $862.80 | 2021-2024 | Xtandi, Padcev |
| Astrazeneca Pharmaceuticals LP | $652.10 | 2021-2024 | Enhertu |
| Glaxosmithkline, LLC. | $640.40 | 2021-2024 | Zejula, Jemperli |
| Amgen INC. | $531.32 | 2021-2022 | |
| Seagen INC. | $462.84 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $389.03 | 2021-2023 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $369.97 | 2021-2022 | |
| Janssen Biotech, INC. | $355.47 | 2021-2022 | |
| Kite Pharma, INC. | $341.19 | 2021-2022 | |
| Puma Biotechnology, INC. | $322.49 | 2021-2022 | |
| Pfizer INC. | $283.56 | 2021-2022 | |
| Myovant Sciences INC. | $283.16 | 2021-2022 | |
| Lilly USA, LLC | $261.08 | 2021-2024 | |
| Daiichi Sankyo INC. | $237.02 | 2021-2022 | |
| Genzyme Corporation | $218.60 | 2021-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Von Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.